Data / Form D filings / Linus Biotechnology Inc.
Linus Biotechnology Inc.: Form D filings
Linus Biotechnology Inc., a biotechnology company in North Brunswick, NJ, filed 3 Form D notices with the SEC between 2022 and 2024. The latest, on August 12, 2024, reports $6.1 million sold of a $10 million offering to 4 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 675 US 1, North Brunswick, NJ, 08902
- Phone
- (917) 373-9740
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2020
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1918153
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 12, 2024 | New notice | $9,999,998 | $6,149,995 | $3,850,003 | 4 | Jul 29, 2024 | sec.gov |
| May 26, 2023 | New notice | $7,999,997 | $7,999,997 | 3 | May 19, 2023 | sec.gov | |
| Mar 22, 2022 | New notice | $17,496,637 | $17,496,637 | 14 | Mar 11, 2022 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Rafi Syed | Director | |
| Amol Deshpande | Director | |
| Ashok Krishnamurthi | Director | |
| Manish Arora | Executive Officer, Director |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
- Bullseye Biodevices, Inc. $1.3 million · Aug 10, 2026
- Hepion Pharmaceuticals, Inc. $3.1 million · Aug 5, 2026
Every Form D from the week of Aug 12, 2024 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Linus Biotechnology Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.